Liver X receptors induce antiproliferative effects in basal‐like breast cancer
Molecular Oncology · 2023
DOI: 10.1002/1878-0261.13476 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2023. Verfasst von Mads Haugland Haugen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Biology, Oslo University Hospital Oslo, Norway. Hauptthemen laut MEDLINE: Orphan Nuclear Receptors, Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Helse Sør-Øst RHF, National Institutes of Health.
Abstract (Originalsprache)
Liver X receptors (LXRs) are nuclear transcription factors important in the regulation of cholesterol transport, and glucose and fatty acid metabolism. The antiproliferative role of LXRs has been studied in a variety of malignancies and may represent a therapeutic opportunity in cancers lacking targeted therapies, such as triple‐negative breast cancer. In this study, we investigated the impact of LXR agonists alone and in combination with carboplatin in preclinical models of breast cancer. In vitro experiments revealed a dose‐dependent decrease in tumor cell proliferation in estrogen receptor‐positive breast cancer cells, whereas LXR activation in vivo resulted in an increased growth inhibitory effect in a basal‐like breast cancer model (in combination with carboplatin). Functional proteomic analysis identified differences in protein expression between responding and nonresponding models related to Akt activity, cell‐cycle progression, and DNA repair. Furthermore, pathway analysis suggested that the LXR agonist in combination with carboplatin inhibits the activity of targets of E2F transcription factors and affects cholesterol homeostasis in basal‐like breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Tumor Biology, Oslo University Hospital Oslo, Norway.
- Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Norway.
- Department of Oncology, Oslo University Hospital, Norway.
- Insitute for Clinical Medicine, University of Oslo, Norway.
- Department of Research and Innovation, Vestre Viken Hospital Trust, Drammen, Norway.
- Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
ORCID-Profile: Hedda von der Lippe Gythfeldt, Elisabetta Marangoni, Olav Engebraaten
Förderung
- NCI NIH HHS
- Helse Sør-Øst RHF
- National Institutes of Health
Zitieren
APA
Haugen, M. H., von der Lippe Gythfeldt, H., Egeland, E. V., Svartdal Normann, L., Pandya, A. D., Vedin, L. L., Juell, S., Tenstad, E., Øy, G. F., Kristian, A., Marangoni, E., Sørlie, T., Steffensen, K., Maelandsmo, G. M., & Engebraaten, O. (2023). Liver X receptors induce antiproliferative effects in basal‐like breast cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.13476
Vancouver
Haugen MH, von der Lippe Gythfeldt H, Egeland EV, Svartdal Normann L, Pandya AD, Vedin LL, et al. Liver X receptors induce antiproliferative effects in basal‐like breast cancer. Molecular Oncology. 2023. doi:10.1002/1878-0261.13476
BibTeX
@article{Haugen2023,
author = {Haugen, Mads Haugland and von der Lippe Gythfeldt, Hedda and Egeland, Eivind Valen and Svartdal Normann, Lisa and Pandya, Abhilash D and Vedin, Lise-Lotte and Juell, Siri and Tenstad, Ellen and Øy, Geir Frode and Kristian, Alexandr and Marangoni, Elisabetta and Sørlie, Therese and Steffensen, Knut and Maelandsmo, Gunhild Mari and Engebraaten, Olav},
title = {Liver X receptors induce antiproliferative effects in basal‐like breast cancer},
journal = {Molecular Oncology},
year = {2023},
doi = {10.1002/1878-0261.13476}
}
EUVIMED